Drugmaker Vivus settles with biggest shareholder

Jul 19, 2013

(AP)—Obesity drugmaker Vivus has agreed to a settlement with its biggest shareholder, which has been fighting for greater control of the company. A long-time drug executive backed by the shareholder will become CEO and the board will be reconfigured.

First Manhattan Co.—which owns 9.9 percent of Vivus' outstanding stock—was waging a proxy fight with Vivus Inc. and said it was in position to win when Vivus adjourned voting on a slate of new directors.

The shareholder sued Vivus earlier this week, as it tried to stop the drugmaker and its representatives from soliciting proxies or votes for the company's annual shareholder meeting. The investment firm also wanted the court to certify disputed results of the election of Vivus' directors, and to stop the Mountain View, California, company's current directors from taking any further action on behalf of Vivus.

As part of the settlement, Anthony Zook—who previously worked at AstraZeneca and has the support of First Manhattan—is expected to be named Vivus' new CEO. Zook was president of MedImmune Inc. before MedImmune was acquired by AstraZeneca, and he was head of global commercial operations for AstraZeneca PLC until February.

Zook would succeed Leland Wilson, who has served as CEO and a director of Vivus since 1991. Wilson has agreed to serve as an adviser to help with the transition process.

Vivus' board will also expand from nine to 11 members. Four directors are resigning, and First Manhattan's six nominees will join the board. Among those resigning from the Vivus board are Charles Casamento Ernest Mario, Linda Shortliffe, Peter Tam and Wilson. First Manhattan's six nominees include Michael James Astrue, Samuel Colin, Alexander Denner, Johannes Kastelein, David York Norton and Herman Rosenman.

The lawsuit First Manhattan filed in the Court of Chancery in the State of Delaware was just the latest action in a dispute that started in March. First Manhattan had criticized Vivus over its weight loss drug Qsymia, saying that the launch was unsuccessful. It initially wanted to replace Vivus' entire board and said that Vivus should change its U.S. business strategy and work to get Qsymia approved in Europe.

Vivus adjourned its annual shareholders meeting Thursday. It expects to hold the meeting no later than 30 days from July 15.

Explore further: Judge approves $450 mn deal in Apple ebook suit

1 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

FDA approves highly anticipated weight-loss pill

Jul 18, 2012

(AP) — The Food and Drug Administration on Tuesday approved a new weight loss drug from Vivus Inc. that many doctors consider the most effective therapy in a new generation of anti-obesity pills designed to help patients ...

FDA to decide on Qnexa obesity drug in July

Apr 10, 2012

US regulators will decide in July whether to approve Qnexa, the first obesity drug in more than a decade, extending the initial deadline by three months, the California-based drug-maker VIVUS said.

FDA panel backs previously rejected obesity pill

Feb 22, 2012

(AP) -- A panel of advisers to the Food and Drug Administration overwhelmingly backed approval for a highly anticipated anti-obesity pill called Qnexa, a drug which the FDA previously rejected due to safety concerns.

Vivus weight loss drug faces FDA panel this week

Jul 13, 2010

(AP) -- Vivus Inc.'s experimental drug Qnexa was effective in cutting weight, the Food and Drug Administration said Tuesday, while acknowledging lingering concerns over the drug's nervous system and psychiatric side effects.

FDA rejects highly-anticipated diet drug Qnexa

Oct 29, 2010

(AP) -- Federal health regulators have decided not to approve an experimental diet pill called Qnexa, which had been touted by many experts as the most promising weight-loss drug in more than a decade.

Recommended for you

Dish restores Turner channels to lineup

23 hours ago

Turner Broadcasting channels such as Cartoon Network and CNN are back on the Dish network after being dropped from the satellite TV provider's lineup during contract talks.

'Call of Duty' blasts past $10 bn in sales

Nov 20, 2014

Blockbuster military shooter video game "Call of Duty" has blasted past $10 billion in lifetime sales, propelled by demand for the latest installment in the 11-year-old franchise.

Square's point-of-sale service goes global

Nov 20, 2014

Financial services startup Square is taking aim at cash registers across the globe, making its point-of-sale software available internationally in English, Spanish, French and Japanese.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.